2.07
7.17%
-0.16
NanoViricides Inc Borsa (NNVC) Ultime notizie
NanoViricides Inc (NNVC) requires closer examination – US Post News - US Post News
US Post News
StockNews.com Initiates Coverage on NanoViricides (NYSE:NNVC) - Defense World
Defense World
NNVC’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
The InvestChronicle
NanoViricides Has Filed its Quarterly Report | Ap | thederrick.com - Oil City Derrick
Oil City Derrick
NanoViricides Has Filed its Quarterly Report - Yahoo Finance
Yahoo Finance
NanoViricides shares gain as new data shows lead drug asset's strong activity against RSV - Proactive Investors USA
Proactive Investors USA
A Novel Broad-Spectrum Antiviral with Activity Against RSV - Oil City Derrick
Oil City Derrick
A Novel Broad-Spectrum Antiviral with Activity Against RSV - Yahoo Finance
Yahoo Finance
NanoViricides CEO discusses NV-387's broad-spectrum antiviral potential - Proactive Investors USA
Proactive Investors USA
NanoViricides to showcase lead drug asset's progress at global conference - Proactive Investors USA
Proactive Investors USA
NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City - Miami Herald
Miami Herald
NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City - Oil City Derrick
Oil City Derrick
NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City - Miami Herald
Miami Herald
NanoViricides Reports Research with NV-387 Showing Promising Results Against Multiple Viruses - Proactive Investors Australia
Proactive Investors Australia
Check Out NanoViricides Inc (NNVC)'s Trade Data Rather Than the Analysts' Views – Sete News - SETE News
SETE News
NanoViricides (NYSE:NNVC) Now Covered by StockNews.com - Defense World
Defense World
NanoViricides says lead asset shows antiviral activity against Smallpox and Mpox - Proactive Investors UK
Proactive Investors UK
NanoViricides Inc (NNVC) deserves closer scrutiny – US Post News - US Post News
US Post News
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox - Sacramento Bee
Sacramento Bee
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox - Oil City Derrick
Oil City Derrick
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox - Miami Herald
Miami Herald
NanoViricides drug asset shows 'superior antiviral effects' against Influenza A - Investing.com Canada
Investing.com Canada
NanoViricides drug asset shows 'superior antiviral effects' against Influenza A - Proactive Investors USA
Proactive Investors USA
A Novel Broad-Spectrum Antiviral with Activity Against Influenza A - Oil City Derrick
Oil City Derrick
A Novel Broad-Spectrum Antiviral with Activity Against Influenza A - Yahoo Finance
Yahoo Finance
StockNews.com Initiates Coverage on NanoViricides (NYSE:NNVC) - Defense World
Defense World
NanoViricides completes Phase 1 trial for respiratory viral infection candidate - Proactive Investors UK
Proactive Investors UK
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon - Charlotte Observer
Charlotte Observer
NanoViricides (NYSE:NNVC) Earns Sell Rating from Analysts at StockNews.com - Defense World
Defense World
NanoViricides (NASDAQ: NNVC) Hits Key Milestones For Its Virus-Fighting Drug Candidate NV-387 In 2023; Mo - Benzinga
Benzinga
NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed ... - Yahoo Finance
Yahoo Finance
NanoViricides: Fiscal Q2 Earnings Snapshot - Quartz
Quartz
Nanoviricides: Phase Ia/b healthy participant dosing completed; pox virus data - Proactive Investors UK
Proactive Investors UK
NanoViricides' Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox - Global Biodefense
Global Biodefense
Nanoviricides: COVID-19 therapy trial underway, RSV trial to follow - Proactive Investors Australia
Proactive Investors Australia
NanoViricides commences clinical trials for its broad-spectrum antiviral drug NV-CoV-2 - Proactive Investors UK
Proactive Investors UK
NanoViricides is leveraging its unique nanoviricide platform technology to create first-in-class drugs against viruses - Proactive Investors USA
Proactive Investors USA
NNVC: NanoViricides Technology Ready to Enter the Clinic - Yahoo Finance
Yahoo Finance
Nanoviricides completes IND-enabling work for NV-CoV-2 - BioWorld Online
BioWorld Online
The 7 Best Nanotechnology Stocks To Buy For %currentmonth% %currentyear% - The Stock Dork
The Stock Dork
Booster Shots Might Not Be Enough to Beat Omicron, According to Some Nanotech Experts - Nanoviricides (AM - Benzinga
Benzinga
NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development - PR Newswire
PR Newswire
Nanomedicine Company Makes "Nanomachines" that Attack Viruses - Yahoo Finance
Yahoo Finance
Dr. Anil R. Diwan Leads NanoViricides In Fight Against COVID-19 - Forbes India
Forbes India
Cashing in on coronavirus: Small biopharma company NanoViricides sees stock soar on treatment claims - CNBC
CNBC
Covid-Linked Stocks Rally on Trump's 'Surprise' Hint, Day Trades - Bloomberg
Bloomberg
NanoViricides Will Return To $3-$5 As Soon As The Coronavirus Newsflow Fades (NYSE:NNVC) - Seeking Alpha
Seeking Alpha
Company News For Jan 28, 2020 - Yahoo News UK
Yahoo News UK
Inovio’s stock soars after receiving grant to develop coronavirus vaccine - MarketWatch
MarketWatch
18 Medical Stocks To Watch Amid The Coronavirus Outbreak - Inovio Pharmaceuticals (NASDAQ:INO), Novavax ( - Benzinga
Benzinga
Capitalizzazione:
|
Volume (24 ore):